Medincell has teamed up with AbbVie to develop and commercialize up to six innovative long-acting injectable (LAI) therapies. This collaboration capitalizes on Medincell’s commercial-stage LAI technology and development expertise and AbbVie’s clinical development and commercialization capabilities.
Medincell will receive an upfront payment of $35 million and potential milestones of up to $1.9 billion based on development and commercial success. Additionally, royalties on worldwide sales are included in the agreement.
The first LAI program candidate has been selected, with formulation activities underway. AbbVie will oversee each program’s clinical development, regulatory approval, manufacturing, and commercialization.
Medincell’s BEPO® technology enables precise drug delivery over extended periods through subcutaneous or local injections. The first BEPO®-based treatment, UZEDY® (distributed by Teva), has been approved by the FDA for the treatment of schizophrenia.
This collaboration is a testament to the growing recognition of LAIs as a promising treatment modality that addresses adherence issues, enhances efficacy, and reduces environmental impact. Medincell and AbbVie aim to leverage their combined strengths to bring innovative therapeutic solutions to patients globally.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
